Compare Amgen, Inc. (AMGN) vs Msci Inc (MSCI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs Msci Inc — how do they compare? Amgen, Inc. trades at $362.14 (market cap $196.12B), while Msci Inc trades at $604 (market cap $44.02B). The key difference: Amgen, Inc. is far larger — about 4.5× Msci Inc's market cap, and Amgen, Inc. pays the higher dividend (2.77%). Which is the better fit depends on your goals.
| AMGN | MSCI | |
|---|---|---|
Market Cap | $196.12B | $44.02B |
Sector | Health | Financials |
52-Week High | $388.16 | $643.83 |
52-Week Low | $271.18 | $511.84 |
Enterprise Value | $241.41B | $50.19B |
Dividend Yield | 2.77% | 1.36% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
MSCI trades at $604.71, up 0.23% today, with a bullish technical signal and strong support at $595. The stock shows robust fundamentals with revenue growth to $3.13B in 2025 and a net income margin of 40.74%, though valuations are elevated with a P/E of 34.54. Recent news highlights strategic partnerships with UBS and acquisitions to enhance its private markets and climate risk capabilities.
Outlook is positive given consistent earnings beats and a consensus price target of $718.14, but risks include high debt levels and reliance on market data demand. Analyst sentiment is strongly bullish with 73% buy ratings, supporting potential upside if execution continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Msci Inc
MSCI describes its mission as enabling investors to build better portfolios for a better world. MSCI's largest and most profitable segment is its index segment, where it provides benchmarking to asset managers and asset owners. In addition, it boasts over $1 trillion in ETF assets linked to MSCI indexes. The MSCI analytics segment provides portfolio management and risk management analytics software to asset managers and asset owners. MSCI's all other segment was broken out into ESG and climate and private assets segments in 2021. In ESG and climate, MSCI provides ESG data to the investment industry. In the private assets side, MSCI provides real restate reporting, market data, benchmarking, and analytics to investors and real estate managers.
Read more on MSCI →
